- Research & Development
- About us
- Invest in us
- Malaria & medicines
Interactive R&D portfolio
MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.
The MMV project portfolio is updated quarterly.
- Download MMV Supported Projects, 1Q 2015 [350Kb]
- Download the global malaria portfolio, 1Q 2015 [470Kb]
- Download the global malaria portfolio, classified by therapeutic type, 1Q 2015 [625Kb]
For more information about the global malaria portfolio, read the article: The Global Portfolio of New Antimalarial Medicines Under Development.